EBBP acts to derepress the transcription of RARb2 (retinoic acid receptor β2) and CYP26A1 (cytochrome P450 family 26 subfamily A member 1), by modifying histone acetylation in retinoid-resistant cancer cells [281]. Here, CYP26A1 is linked to cancer.